Dr. Adam E. Cohen
Neurotechnologies and Disease Modeling Expertise
Adam E. Cohen is a professor in the departments of Chemistry and Chemical Biology and Physics at Harvard, with secondary appointments in the Center for Brain Science and the Harvard Stem Cell Institute. He is also an investigator with the Howard Hughes Medical Institute. At Harvard, Adam and his lab have developed numerous tools to study biological molecules and cells, most notably Optopatch technology. This first-of-its-kind technology uses genetically encoded fluorescent reporters to examine electrical activity in neurons. The Optopatch technology is commercially licensed exclusively to Q-State, where it is used to characterize cellular models of nervous system disorders. Adam has received Young Investigator Awards from the Office of Naval Research, the Dreyfus Foundation, the Sloan Foundation, and many other organizations. Technology Review Magazine named Adam one of the top 35 US technological innovators under the age of 35, Popular Science named him one of their “Brilliant Ten” top young scientists, and President Obama awarded him a Presidential Early Career Award for Scientists and Engineers. Adam holds an A.B. in chemistry and physics from Harvard, a Ph.D. in experimental biophysics from Stanford, and a Ph.D. in theoretical physics from the University of Cambridge. At Q-State, Adam provides scientific and strategic advice on a wide range of topics.
Dr. Kevin Eggan
Disease Modeling Expertise
Kevin Eggan is a professor in the department of Stem Cell and Regenerative Biology at Harvard and Director of the Stem Cell program at the Broad Institute’s Stanley Center. He garnered international recognition for his seminal work in stem cell biology, receiving the MacArthur Foundation “Genius Grant” in 2006 and being selected as a Howard Hughes Medical Institute Early Career Scientist. His current research focuses on using stem cell technologies to better understand nervous system disorders such as amyotrophic lateral sclerosis (ALS) and schizophrenia, with the aim of developing new therapeutics. In his role as an advisor to Q-State, Kevin provides invaluable disease modeling expertise and helps to inform the company’s scientific strategy. Kevin received a B.S. from the University of Illinois and a Ph.D. from the Massachusetts Institute of Technology.
Dr. Orrin Devinsky
Dr. Orrin Devinsky is the Director of the NYU Comprehensive Epilepsy Center and the Saint Barnabas Institute of Neurology and Neurosurgery (INN). He is also a Professor of Neurology, Neurosurgery and Psychiatry at NYU Langone School of Medicine. At NYU, Orrin specializes in treating children and adults with epilepsy and also leads clinical studies to better understanding the neurophysiology of epilepsy and testing the safety and efficacy of new treatments. His research has been instrumental in developing many of the anti-epileptic drugs available on the market or in clinical trials today, and as a result he was selected by TIME Magazine as one of the 50 most influential people in healthcare (2018). As an advisor to Q-State, Orrin helps connect the company to the epilepsy community and provides guidance on the company’s modeling and drug screening services offered to patients with epilepsy. He received a B.S. and M.S. from Yale University and an M.D. from Harvard Medical School.
Dr. Jennifer Levin Carter
Precision Medicine Market Strategy
Jennifer Levin Carter founded N-of-One, Inc. the leader in the clinical interpretation of molecular diagnostic tests in oncology. She currently serves as N-of-One’s President and Chief Medical Officer. Dr. Carter (Jen) has a passion for finding solutions to improve patient care with deep expertise in creation and implementation of systems and platforms supporting precision medicine. Her particular focus has been the development of knowledge and systems that enable greater patient and physician access to novel diagnostics and therapeutic strategies. Since 2012, she has participated as a presenter, expert panelist, or moderator at more than 25 industry conferences, events, and symposiums and serves on multiple industry advisory boards. A board-certified internist and seasoned entrepreneur, Jen has more than 20 years of experience evaluating existing and emerging markets, new medical technologies, and early-stage companies in the health care field. In establishing N-of-One, Jen brought to the enterprise extensive experience analyzing market opportunities, creating services to improve health care delivery, forming expert teams, and identifying business synergies. She leverages her expertise in these areas to advise Q-State on the company’s precision medicine strategy, including its service offerings, physician engagement methods, and growth opportunities. Prior to launching N-of-One, Jen was a consultant and analyzed biotechnology, pharmaceutical, and medical device firms on behalf of investors. Jen has B.S. degrees in Biochemistry and Biophysics from Yale University, an M.D. from Harvard Medical School, an M.P.H. from The Harvard School of Public Health and is currently pursuing an MBA in the Executive MBA program at MIT.
Dr. Matthew Might
Interpretive Genomics & Community Engagement Expertise
Dr. Matthew Might is the Director of the Hugh Kaul Precision Medicine Institute at the University of Alabama at Birmingham (UAB) School of Medicine. There, he leverages his expertise in genomics and informatics to drive the Institute’s strategic direction. Formerly, Matthew served as a member of the White House’s Precision Medicine Initiative and was an Associate Professor in the School of Computing at the University of Utah. He received a CAREER Award from the National Science Foundation, and in 2014 he was appointed one of six Presidential Scholars at the University of Utah. Matthew received a Ph.D. in Computer Science from Georgia Institute of Technology. His son, Bertrand, was the first patient ever discovered with a rare disorder known as N-Glycanase deficiency. Matt posted an essay online that catalyzed the creation of the NGLY1 patient community, the remarkable aftermath of which has been chronicled in publications such as The New Yorker and Der Spiegel.
Dr. Sudhir Agrawal
Antisense Oligonucleotide Expertise
Sudhir Agrawal, D. Phil, FRSC is a Visiting Professor in the Department of Medicine at The University of Massachusetts Medical School, a member of the Business Advisory Board of The Harvard Medical School’s Initiative for RNA Medicine, and a member of advisory board of Lytix biopharma. He is founder and member of Arnay Sciences LLC. He is also a founder of Idera Pharmaceuticals and had held various leadership roles within the company, including Chairman, CEO, President of Research, and Chief Scientific Officer. Sudhir’s research interests focus on the discovery and development of nucleic acid therapeutics, including antisense oligonucleotides (ASOs). He has edited four books on oligonucleotides and antisense technology, published hundreds of research papers on these topics, and is listed as a co-inventor of more than 400 patents worldwide. Sudhir provides guidance to Q-State on the therapeutic application of ASOs for rare neurological disorders.
Dr. William Pullman
Drug Development & Regulatory Expertise
As President of Proximagen, an early clinical stage drug development company, Dr. William (Bill) Pullman oversees the company’s strategic direction and scientific affairs, including pipeline selection and development, and all clinical, medical, and regulatory operations. Before joining Proximagen, Bill served as Chief Scientific Officer of Upsher-Smith Laboratories. He also formerly held positions as Chief Research and Development Officer and Chief Development Officer at Dyax Corp., Chief Medical Officer at Cubist Pharmaceuticals, and Senior Vice President, Exploratory Development at TransForm Pharmaceuticals. Bill completed his primary medical training at the University of Western Australia and is a fellow of the Royal Australian College of Physicians. He also received a Ph.D. in Medicine and Clinical Science (Immunology) from the Australian National University.